manalikamdar @mana1981

HematoOncologist, eternal optimist, passionate about making every moment count Denver, CO Joined October 2009

Tweets

699
Followers

733
Following

436
Likes

3K

CU Cancer Center @CUCancerCenter

2 days ago

#BloodCancerAwarenessMonth: The latest study from CU Cancer Center member Manali Kamdar (@mana1981), MD, focuses on CD19 CAR T-cell therapies for lymphoma, and contributes to an FDA regulatory change that she says could broaden access ⬇️ news.cuanschutz.edu/cancer-center/…

1 2 8 313 0

CU Lymphoma Program @CULymphoma

5 days ago

Welcome to our new @CUHematology faculty Dr. Cassandra Duarte! Dr. Duarte is joining our @CULymphoma program with specialization in aggressive B-cell lymphomas as well as mastocytosis and histiocytic disorders. #lymsm

0 2 10 442 1

Download Image

Ajay Major, MD, MBA @majorajay

2 weeks ago

Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new @JNCI_Now manuscript highlights need for tailored screening guidelines. #onctwitter #survonc academic.oup.com/jnci/advance-a…

1 3 13 925 1

Download Image

MarkHarden @MarkHardenCUMed

3 weeks ago

“It’s a huge win for patients": Research led by @CUCancerCenter member @mana1981, MD, has contributed to a change that could broaden access to a form of CAR T-cell therapy for lymphoma. My latest story for @CUMedicalSchool at @CUAnschutz. #cucityofhealth news.cuanschutz.edu/cancer-center/…

0 5 16 619 0

Raul Cordoba, MD, PhD @DrRaulCordoba

4 weeks ago

#Hematology Outcomes of bispecific antibody therapy after #CARTcell failure in relapsed/refractory large B-cell #lymphoma #DLBCL | Blood Advances | American Society of Hematology #lymsm ashpublications.org/bloodadvances/…

0 9 35 2K 6

Toby Eyre @tobyeyre82

a month ago

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis ashpublications.org/bloodadvances/…

4 16 42 3K 17

Vinay Jain @vinaykjain17

4 weeks ago

⁦@DAVAOnc⁩ #BermudaHeme Degraders and glues in heme malignancies

0 1 5 277 0

Download Image

DAVA Oncology @DAVAOnc

4 weeks ago

Golcadomide, a novel CELMoD, demonstrates strong activity & manageable safety in R/R FL, incl. post-lenalidomide/T-cell therapy patients. Data shared by @mana1981 (@CUAnschutz) at #DAVAHeme. #BloodCancer

0 1 6 330 2

Download Image

DAVA Oncology @DAVAOnc

4 weeks ago

Dr. @mana1981 (@CUAnschutz) presented early APOLLO data for MT-601, a non-engineered MAR-T targeting 6 antigens: 78% NHL pts responded at first assessment; no ICANS or DLTs; 1 G1 CRS. #DAVAHeme #Lymphoma

0 2 8 378 2

Download Image

DAVA Oncology @DAVAOnc

4 weeks ago

Preliminary safety & tolerability data from Phase I CD19x22 CAR-T in R/R aggressive NHL show robust in vivo expansion, low exhaustion & early efficacy (CR 25%, PR 12.5%) with manageable IEC-HS, presented by @mana1981 from @UCCancerCenter at #davaheme

0 3 7 566 1

Download Image

Vinny Pizzuti @vpizzuti44

2 months ago

I am happy to announce I was selected by @ASH_hematology to receive the ASH HONORS Award! Excited for this project studying PET/CT radiomics in DLBCL. Grateful to @mana1981 for her mentorship and ASH for the support! #ASHAwards #Fight4Hematology @CULymphoma @CUDeptMedicine

3 6 35 4K 1

Download Image

manalikamdar @mana1981

2 months ago

Thrilled to share our 3‑year follow‑up results from the phase III TRANSFORM trial of lisocabtagene maraleucel vs standard of care in 2L R/R LBCL⁩ 🎉 ⁦@CUCancerCenter⁩ ⁦⁩ ⁦@CUHematology⁩ ⁦@lymphoma⁩ ⁦@WomenInLymphoma⁩⁦ ascopubs.org/doi/10.1200/JC…

1 10 55 3K 5

Matt Lunning D.O. FACP @lymphomaphilia

2 months ago

Mark this Day! Thank you FDA! A major step in increasing access to CAR-T! In my opinion, 4 weeks was like a sentence, 2 weeks is more like a vacation. Time to engage our referring teams to give them the education and assistance to make this a success . targetedonc.com/view/fda-appro…

0 3 30 1K 3

Ajay Major, MD, MBA @majorajay

3 months ago

>1500 trial & @CIBMTR pts who received liso-cel: - 96-97% of CRS events were before D+15 - 88-95% ICANS before D+15 - no G5 CRS/ICANS after D+15 Do we really need a full 30 days of monitoring after liso-cel? @mana1981 #lymsm #tcellrx #18ICML

0 5 10 903 3

Download Image

drsairahahmed @drsairahahmed

3 months ago

Navigating CART for Lymphoma in 2025 - great session at #EHA2025 with @mana1981 @KRejeski and the OG Prof Zinzani #CART #lymsm

4 3 20 835 0

Download Image

VJHemOnc @VJHemOnc

3 months ago

It's always a pleasure to catch up w/ Manali Kamdar (@mana1981) of @CUCancerCenter 😄 At #ASCO25, she provided insight into research exploring how to optimize post-CAR T-cell monitoring in patients with #lymphoma receiving liso-cel: 🎥 ow.ly/eiKO50W3RXw #LYMsm #DLBCL

9 2 10 834 2

manalikamdar @mana1981

3 months ago

You made my day James !!! Thank you !!!

Sunnie Kim, MD @SunnieSKim

3 months ago

You made my day James !!! Thank you !!!

10 3 84 6K 1

Download Image

0 3 25 1K 0

Ajay Major, MD, MBA @majorajay

4 months ago

Elated to be joining the @ASH_hematology Clinical Research Training Institute (CRTI) in 2025! Eager to work on our research program utilizing PROs to improve treatment decision-making in indolent lymphomas. Deeply grateful to my mentors Drs. @hawkeyestudts & @mana1981. #lymsm

3 5 66 3K 2

Download Image

Ajay Major, MD, MBA @majorajay

4 months ago

2nd myeloid cancers post CD19 CAR @NGazeau14 - 539 pts, all B-NHL - 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!) - ⬆️ MCV & high-grade ICANS risk factors for t-MN - 86% of t-MN had pre-CAR mutations Important retrospective study for #tcellrx. #lymsm nature.com/articles/s4137…

2 14 32 2K 12

Download Image

CU Lymphoma Program @CULymphoma

5 months ago

Our @CULymphoma faculty Dr. @majorajay contributed to a multicenter study of venetoclax in relapsed/refractory Waldenstrom macroglobulinemia, now published @BloodCancerJnl. #lymsm pmc.ncbi.nlm.nih.gov/articles/PMC12…